Vanda

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023

Retrieved on: 
Wednesday, February 1, 2023
Vanda, Pharmaceutical industry

WASHINGTON, Feb. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes.

Key Points: 
  • WASHINGTON, Feb. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes.
  • Vanda will host a conference call at 4:30 PM ET on Wednesday, February 8, 2023, during which management will discuss the fourth quarter and full year 2022 financial results and other corporate activities.
  • To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 4734670.
  • Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 6, 2023
Conference, Software, Vanda, Communications satellite, Online shopping, Pharmaceutical industry

WASHINGTON, Jan. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 12, 2023.

Key Points: 
  • WASHINGTON, Jan. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 12, 2023.
  • The corporate presentation given at the J.P. Morgan Healthcare Conference may be accessed live on Vanda's corporate website, www.vandapharma.com .
  • Investors are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations.
  • A link to the archived conference will be available on Vanda's website for a period of approximately 30 days.

Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch

Retrieved on: 
Friday, December 16, 2022
District court, ANDA, LQ, Vanda, Teva, United States courts of appeals, United States Court of Appeals for the Federal Circuit, Court, Dura Pharmaceuticals, Inc. v. Broudo, Patient, Ciba-Geigy Canada Ltd v Apotex Inc, Teva Pharmaceuticals, Federal Circuit Court of Australia, Generic drug, Apotex

WASHINGTON, Dec. 16, 2022 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its appeal of the recent HETLIOZ ANDA litigation ruling.

Key Points: 
  • WASHINGTON, Dec. 16, 2022 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its appeal of the recent HETLIOZ ANDA litigation ruling.
  • Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
  • For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.
  • For full U.S. Prescribing Information for HETLIOZand HETLIOZ LQ, including indication and Important Safety Information, visit www.hetlioz.com .

Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation

Retrieved on: 
Tuesday, December 13, 2022
District court, Vanda, Analysis, Sumathi Best Television Current Reporting Award, Teva, Union, United States courts of appeals, United States Court of Appeals for the Federal Circuit, Court, Financial condition report, Patient, 1836 U.S. Patent Office fire, Conversation, Annual report, Capsule, Ciba-Geigy Canada Ltd v Apotex Inc, Risk, Teva Pharmaceuticals, Result, Patent, Generic drug, Apotex

WASHINGTON, Dec. 13, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ ANDA Litigation.

Key Points: 
  • WASHINGTON, Dec. 13, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ ANDA Litigation.
  • HETLIOZ is also approved in the European Union and is not subject to this litigation, nor is generic litigation pending outside of the United States.
  • For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.
  • Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.

Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

Retrieved on: 
Wednesday, October 26, 2022
Patient, Twitter, Nasdaq, Vanda, Renewable energy, Pharmaceutical industry

WASHINGTON, Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2, 2022, after the market closes.  

Key Points: 
  • WASHINGTON, Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2, 2022, after the market closes.
  • Vanda will host a conference call at 4:30 PM ET on Wednesday, November 2, 2022, during which management will discuss the third quarter 2022 financial results and other corporate activities.
  • To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 5456289.
  • For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022

Retrieved on: 
Wednesday, July 27, 2022
Nasdaq, Vanda, Twitter, Patient, Pharmaceutical industry

WASHINGTON, July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes.  

Key Points: 
  • WASHINGTON, July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes.
  • Vanda will host a conference call at 4:30 PM ET on Wednesday, August 3, 2022, during which management will discuss the second quarter 2022 financial results and other corporate activities.
  • To participate in the conference call, please dial 1-800-715-9871(domestic) or 1-646-307-1963 (international) and use passcode 4304469.
  • For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Vanda Pharmaceuticals Announces Presentations at SLEEP 2022

Retrieved on: 
Tuesday, May 31, 2022
Patient, Phenotype, Autism spectrum, RAI1, Vanda, SMS, Twitter, Sleep, Nasdaq

WASHINGTON, May 31, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022.

Key Points: 
  • WASHINGTON, May 31, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022.
  • The following scientific posters will be presented:
    Title: "Enrichment of RAI1 genetic aberrations associated with sleep disturbances in SMS, in Autism Spectrum Disorder"
    Title: "A novel missense variant in Melanopsin associates with delayed sleep phenotype: whole-genome sequencing study"
    For more information on SLEEP 2022, please refer to https://www.sleepmeeting.org/ .
  • Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
  • For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference

Retrieved on: 
Wednesday, May 4, 2022
Vanda, Conference, Software, Bank of America, Patient, Twitter, Nasdaq, Investor

WASHINGTON, May 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 10, 2022.

Key Points: 
  • WASHINGTON, May 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 10, 2022.
  • The corporate presentation given at the BofA Securities 2022 Healthcare Conference may be accessed live on Vanda's corporate website, www.vandapharma.com .
  • A link to the archived conference will be available on Vanda's website for a period of approximately 30 days.
  • For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022

Retrieved on: 
Thursday, April 28, 2022
Patient, Twitter, Nasdaq, Vanda

WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on Thursday, May 5, 2022, after the market closes.  

Key Points: 
  • WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on Thursday, May 5, 2022, after the market closes.
  • Vanda will host a conference call at 4:30 PM ET on Thursday, May 5, 2022, during which management will discuss the first quarter 2022 financial results and other corporate activities.
  • To participate in the conference call, please dial 1-866-688-9426(domestic) or 1-409-216-0816 (international) and use passcode 1355275.
  • For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Retrieved on: 
Thursday, February 17, 2022
Patient, Vanda, Twitter, Nasdaq, Pharmaceutical industry

WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes.  

Key Points: 
  • WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes.
  • Vanda will host a conference call at 4:30 PM ET on Wednesday, February 23, 2022, during which management will discuss the fourth quarter and full year 2021 financial results and other corporate activities.
  • To participate in the conference call, please dial 1-866-688-9426(domestic) or 1-409-216-0816 (international) and use passcode 5373895.
  • For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.